Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

FTSE 100 notches new record after Bank of England cuts rates

London’s blue-chip index smashed through recent highs after experts said the Bank’s announcement gave it ‘a shot of adrenaline’.

The Independent UK

AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site

Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision.

The Independent UK

AstraZeneca ‘very disappointed’ over axed £450m Liverpool vaccine project

As drugmaker reports 38% jump in profits, CEO denies tension with UK government after Speke plant decision

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Blame ministers for AstraZeneca U-turn

Letters: As a health minister in the 1970s, David Owen writes, he would have been too close to industry to allow such a deal to fail

The Guardian - UK

AstraZeneca’s U-turn on £450m Speke expansion ‘deeply disappointing’, says minister

Chris Bryant says reduction of government support was linked to change in drugmaker’s proposed investment

The Guardian - UK

AstraZeneca investment deal ‘didn’t add up for UK taxpayer’, says minister

Science minister Sir Chris Bryant said the Government feels regretful about the plan being ditched and ‘would prefer to have got this over the line’.

Evening Standard

AstraZeneca’s £450m Speke U-turn looks terrible for a pro-growth government

It seems bizarre that ministers and UK’s largest company cannot complete investment in vital life sciences sector

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

What the papers say – February 1

Here are the major stories grabbing the attention on Saturday’s news stands.

Evening Standard

What has the UK Covid inquiry learned so far about vaccines and treatments?

In fourth part of the inquiry, questons were asked about vaccine trials, procurement and the UK’s preparedness for future pandemics

The Guardian - UK

AstraZeneca cancels £450m vaccine plant in UK after Government 'own goal' in blow to Rachel Reeves growth plan

The pharmaceutical giant claimed the Labour Government failed to match Tory predecessor’s offer of help for its investment in Merseyside

Evening Standard

Fresh blow for Rachel Reeves as AstraZeneca scraps £450m investment in UK vaccine plant

The pharmaceutical giant claimed the Labour Government failed to match its predecessor’s offer but the cancelled project is a blow to the chancellor’s growth agenda

The Independent UK

AstraZeneca axes £450m vaccine plant in Liverpool, blaming state funding cut

Days after Rachel Reeves highlighted life sciences as UK strength, firm decides against site expansion

The Guardian - UK

Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket

This biotech stock is a promising buy, but it does come with risks.

Barchart

Daily pill on NHS offers new hope for hundreds with lung cancer

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Well-known medics to appear in front of UK Covid probe

Module four of the inquiry is looking at the development and rollout of vaccines in the UK.

The Guardian - UK

GSK to buy US cancer drug firm IDRx for up to $1.15bn

Massachusetts-based company is working on new treatments for gastrointestinal cancers

The Guardian - UK

From the Beatles to biologics – how Liverpool became a life science hotspot

The city has a long history with tropical medicine and is now home to one of the largest biotech clusters in Europe

Fortune

Breast cancer drug Lynparza reduces risk of death by 28% in patients diagnosed early, clinical trial shows

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer

AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression outcomes in treated patients.

Top News

Astrazeneca Appoints New China Head Amid Investigation Concerns

AstraZeneca appoints Iskra Reic as new head of China operations amid investigations and challenges in the pharmaceutical industry in China.

The Conversation

First new treatment for asthma and COPD in half a century – new study

Every 30 seconds, someone in the world will experience a flare-up of their asthma or chronic obstructive pulmonary disease (COPD) symptoms. For decades, the standard treatment for these potentially life-threatening episodes has remained unchanged – treatment with steroids, such as prednisolone.

MarketBeat

Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch

Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines.

Benzinga

AstraZeneca's Truqap Demonstrates Progress in Advanced Prostate Cancer Treatment

Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca's Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically

The Guardian - UK

Breast cancer drug blocked for NHS use in England and Wales after talks collapse

National Institute for Health and Care Excellence unable to reach price agreement with manufacturers of Enhertu

The Independent UK

Breast cancer drug blocked for NHS use as price talks break down – leaving charities ‘beyond devastated’

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name Enhertu

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.